Current:Home > InvestEU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail -Pinnacle Profit Strategies
EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail
View
Date:2025-04-13 10:55:54
BRUSSELS (AP) — The European Union on Thursday ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in the 27-nation bloc.
The EU already slapped a $475 million fine on Illumina over the summer for jumping the gun on the acquisition without its consent. Now, the order to unwind the deal “restores competition in the development of early cancer detection tests,” EU antitrust Commissioner Didier Reynders said.
“By ordering Illumina to restore Grail’s independence, we ensure a level playing field in this crucial market to the ultimate benefit of European consumers,” he said.
Illumina said it is reviewing the order to sell Grail. The company also has previously asked the EU’s highest court to rule on its challenge to the bloc’s ability to review the merger.
Allowing the deal to stand would have undermined the credibility of EU regulators. Companies almost invariably play by the rules and wait to complete an acquisition or merger until antitrust authorities have cleared it, according to the European Commission, the EU’s executive arm and top antitrust enforcer.
Illumina announced the acquisition of Grail in 2020, but the commission said the company broke EU merger rules by completing the deal without its consent. The commission prohibited the deal in September 2022.
The EU accused Illumina and Grail of knowingly and deliberately merging before getting clearance in what amounted to a vital infringement of the rules.
Illumina must “restore the situation prevailing before” the acquisition, regulators said, and how Illumina divests itself of Grail also needs EU approval.
Regulators worldwide have targeted the deal. The Federal Trade Commission ordered Illumina to sell Grail earlier this year after finding the merger would “stifle competition and innovation in the U.S. market for life-saving cancer tests.”
The EU said the acquisition would squeeze out competitors and give Illumina too dominant of a position in the market.
San Diego-based Illumina is a major supplier of next-generation sequencing systems for genetic and genomic analysis, while Grail is a health company developing blood tests to try to catch cancer early.
veryGood! (437)
Related
- 'Survivor' 47 finale, part one recap: 2 players were sent home. Who's left in the game?
- NFL schedule today: What to know about Falcons at Eagles on Monday Night Football
- Control of the Murdoch media empire could be at stake in a closed-door hearing in Nevada
- Why Kourtney Kardashian Has No Cutoff Age for Co-Sleeping With Her Kids
- The White House is cracking down on overdraft fees
- Jane’s Addiction cancels its tour after onstage concert fracas
- Taylor Swift's Mom Andrea Swift Shares Sweet Moment with Travis Kelce's Mom
- Abercrombie & Fitch Quietly Put Tons of Chic Styles on Sale – Score an Extra 25% off, Starting at $9
- Jorge Ramos reveals his final day with 'Noticiero Univision': 'It's been quite a ride'
- 2024 Emmys: RuPaul’s Drag Race Stars Shut Down Claim They Walked Out During Traitors Win
Ranking
- NHL in ASL returns, delivering American Sign Language analysis for Deaf community at Winter Classic
- Colleges in Springfield, Ohio, move to online instruction after threats targeting Haitians
- Giving away a fortune: What could Warren Buffett’s adult children support?
- Former Uvalde schools police chief makes first court appearance since indictment
- Most popular books of the week: See what topped USA TODAY's bestselling books list
- New Jersey internet gambling sets new record at $198M in revenue, but land casinos lag
- Lutherans in Walz’s Minnesota put potlucks before politics during divisive election season
- Child trapped between boulders for 9 hours rescued by firefighters in New Hampshire
Recommendation
Are Instagram, Facebook and WhatsApp down? Meta says most issues resolved after outages
Model Bianca Balti Shares Ovarian Cancer Diagnosis
After a mission of firsts, SpaceX Polaris Dawn crew returns safely to Earth
Social media is wondering why Emmys left Matthew Perry out of In Memoriam tribute
This was the average Social Security benefit in 2004, and here's what it is now
Control of the Murdoch media empire could be at stake in a closed-door hearing in Nevada
The Fate of Emily in Paris Revealed After Season 4
An appeals court won’t revive Brett Favre’s defamation lawsuit against Shannon Sharpe